Loading
British surgeon who led BILCAP, the trial that made six months of capecitabine the standard after surgery for bile duct and gallbladder cancer.
John Primrose is professor of surgery at the University of Southampton. He was chief investigator and first author of the 2019 Lancet Oncology report of BILCAP, the UK trial that compared adjuvant capecitabine with observation after resection of biliary tract cancer. The survival benefit in the per-protocol analysis led guidelines to adopt capecitabine as the standard adjuvant treatment.
| Title | Journal | Year |
|---|---|---|
| BILCAP: capecitabine compared with observation in resected biliary tract cancer | The Lancet Oncology | 2019 |
This is the reference European standard against which UK and NHS practice for gallbladder cancer is compared; it treats gallbladder cancer within biliary tract cancer rather than as its own disease.
Adjuvant capecitabine is the standard after resection of intrahepatic and extrahepatic cholangiocarcinoma and gallbladder cancer, endorsed by ASCO and ESMO guidelines.
Shares Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Biliary tract cancer (all types) and the tags biliary, trialist.
Shares Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials and the tags biliary, trialist.
Shares BILCAP, Biliary tract cancer (all types) and the tags biliary, trialist.
Shares Intrahepatic cholangiocarcinoma, Biliary tract cancer (all types) and the tags biliary, trialist.
Shares Intrahepatic cholangiocarcinoma and the tags biliary, trialist.
Shares Biliary tract cancer (all types) and the tags biliary, trialist.
Shares Hassan Malik, Biliary tract cancer (all types) and the tag biliary.
Shares the tags surgery, trialist.